No Data
No Data
Is Chongqing Genrix Biopharmaceutical (SHSE:688443) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Zhixiang Jintai (688443.SH) reported first-quarter results with a net loss of 164 million yuan
Zhixiang Jintai (688443.SH) released its report for the first quarter of 2024, with revenue of 6,330.27...
Guoxin Securities: The pharmaceutical industry is entering an upward inflection point in the medium to long term, and focus on high growth targets in the quarterly report in the short term
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Private Equity Firms in Chongqing Genrix Biopharmaceutical Co., Ltd. (SHSE:688443) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 15% Last Week
Key Insights The considerable ownership by private equity firms in Chongqing Genrix Biopharmaceutical indicates that they collectively have a greater say in management and business strategy The larg
Guoxin Securities: Focus on the immediate needs of medical care, focus on the high growth targets of the first quarter report
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Chongqing Genrix Biopharmaceutical Co., Ltd.'s (SHSE:688443) Intrinsic Value Is Potentially 100% Above Its Share Price
Key Insights The projected fair value for Chongqing Genrix Biopharmaceutical is CN¥61.83 based on 2 Stage Free Cash Flow to Equity Chongqing Genrix Biopharmaceutical is estimated to be 50% undervalu
No Data